<SUBMISSION>
<ACCESSION-NUMBER>0000950124-05-002496
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>2
<PERIOD>20050419
<ITEMS>7.01
<ITEMS>9.01
<FILING-DATE>20050419
<DATE-OF-FILING-DATE-CHANGE>20050419
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>TASER INTERNATIONAL INC
<CIK>0001069183
<ASSIGNED-SIC>3480
<IRS-NUMBER>860741227
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>001-16391
<FILM-NUMBER>05758050
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>7860 EAST MCLAIN DR.
<STREET2>SUITE 2
<CITY>SCOTTSDALE
<STATE>AZ
<ZIP>85260
<PHONE>4809052000
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>7860 EAST MCLAIN DR.
<STREET2>SUITE 2
<CITY>SCOTTSDALE
<STATE>AZ
<ZIP>85260
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>p70509e8vk.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>

<DIV align="center" style="font-size: 12pt"><B>Washington, DC 20549</B>
</DIV>


<P align="center" style="font-size: 10pt"><HR size="1" noshade width="26%" align="center" color="#000000">


<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>


<P align="center" style="font-size: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of<BR>
The Securities Exchange Act of 1934</B>


<P align="center" style="font-size: 10pt">Date of Report (Date of earliest event reported)



<P align="center" style="font-size: 10pt"><B>April&nbsp;19, 2005</B>



<P align="center" style="font-size: 10pt"><HR size="1" noshade width="26%" align="center" color="#000000">


<P align="center" style="font-size: 24pt"><B>TASER International, Inc.</B>


<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware</B><BR>
(State or other jurisdiction of<BR>
incorporation)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>001-16391</B><BR>
(Commission File Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>86-0741227</B><BR>
(IRS Employer<BR>
Identification No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><B>7860 E. McClain Drive, Suite&nbsp;2<BR>
Scottsdale, Arizona 85260</B><BR>
(Address of principal executive offices, including zip code)



<P align="center" style="font-size: 10pt"><B>(480)&nbsp;991-0791</B><BR>
(Registrant&#146;s telephone number, including area code)



<P align="center" style="font-size: 10pt">(Former name or former address, if changed since last report)


<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:


<P align="left" style="font-size: 10pt"><FONT face="Wingdings">&#111;</FONT> Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)


<P align="left" style="font-size: 10pt"><FONT face="Wingdings">&#111;</FONT> Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)


<P align="left" style="font-size: 10pt"><FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))


<P align="left" style="font-size: 10pt"><FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))



<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>





<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<DIV style="font-family: 'Times New Roman',Times,serif">



<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD></TD><TD colspan="8"><A HREF="#000">Item&nbsp;7.01 Regulation&nbsp;FD Disclosure</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#001">Item&nbsp;9.01 Financial Statements and Exhibits</A></TD></TR>
<TR><TD colspan="9"><A HREF="#002">SIGNATURE</A></TD></TR>
<TR><TD colspan="9"><A HREF="#003">INDEX TO EXHIBITS</A></TD></TR>
<TR><TD colspan="9"><A HREF="p70509exv99w1.htm">EX-99.1</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>




<P><DIV style="position: relative; float: left; width: 5%">

<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

</DIV>
<DIV style="position: relative; float: right; width: 92%">
<!-- link2 "Item&nbsp;7.01 Regulation&nbsp;FD Disclosure" -->
<DIV align="left"><A NAME="000"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;7.01 Regulation&nbsp;FD Disclosure</B>


<P align="left" style="font-size: 10pt">In accordance with Securities and Exchange Commission Release No.&nbsp;33-8216, the following
information, which is intended to be furnished under Item&nbsp;12, &#147;Results of Operations and Financial
Condition,&#148; is instead being furnished under Item&nbsp;9, &#147;Regulation&nbsp;FD Disclosure.&#148; This information
shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as
amended (the &#147;Exchange Act&#148;), or incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific
reference in such a filing.


<P align="left" style="font-size: 10pt">On April&nbsp;19, 2005, TASER International, Inc. (the &#147;Company&#148;) issued a press release regarding the
Company&#146;s financial results for its fiscal quarter ended March&nbsp;31, 2005. The full text of the press
release, together with the Statements of Operations and Balance Sheets are attached hereto as
Exhibit&nbsp;99.1.


<!-- link2 "Item&nbsp;9.01 Financial Statements and Exhibits" -->
<DIV align="left"><A NAME="001"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;9.01 Financial Statements and Exhibits</B>


<P align="left" style="font-size: 10pt">(c)&nbsp;Exhibits.


</DIV>
<BR clear="all"><BR>

<P>
<TABLE width="100%" border="0" cellpadding="2" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="1%"></TD>
    <TD width="99%"></TD>
</TR>
<TR valign="top">
    <TD nowrap>99.1&nbsp;</TD>
    <TD>Text of press Release dated April&nbsp;19, 2005 titled &#147;<B>TASER International, Inc. Releases First
Quarter Financial Results</B>,&#148;.</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt">-2-
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<!-- link1 "SIGNATURE" -->
<DIV align="left"><A NAME="002"></A></DIV>

<P align="center" style="font-size: 10pt"><B>SIGNATURE</B>


<P align="left" style="font-size: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto duly authorized.



<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">Dated: April 19, 2005      &nbsp;</TD>
    <TD colspan="3" align="left">TASER International, Inc.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ DANIEL BEHRENDT
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Daniel Behrendt&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt">-3-
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<!-- link1 "INDEX TO EXHIBITS" -->
<DIV align="left"><A NAME="003"></A></DIV>

<P align="center" style="font-size: 10pt"><B>INDEX TO EXHIBITS</B>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="90%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Exhibit</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Number</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Description of Document</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top">99.1
</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Press Release dated April&nbsp;19, 2005.</DIV></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>p70509exv99w1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">



<P align="right" style="font-size: 10pt"><B>EXHIBIT 99.1</B>



<P align="left" style="font-size: 10pt"><B>FOR RELEASE ON April&nbsp;19, 2005 at 7:00 a.m. E.S.T.</B>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>CONTACT:</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Dan Behrendt</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chief Financial Officer</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TASER International, Inc.</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(480) 905-2000</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><B>TASER International,
Inc. Releases First Quarter Financial<BR>
Results</B>



<P align="center" style="font-size: 10pt"><B><I>Company Reports First Quarter Revenue of $10.2 Million</I></B>


<P align="left" style="font-size: 10pt">SCOTTSDALE, AZ, April&nbsp;19, 2004 &#151; TASER International, Inc. (NASDAQ: TASR), a market leader in
advanced non-lethal devices announced that revenues and earnings for the first quarter of 2005 were
$10.2&nbsp;million and $168,000, respectively. The profitability in the quarter was adversely impacted
by increased legal, insurance and professional fees, as well as lower than expected gross margins
resulting from the decline in quarterly revenue. As of March&nbsp;31, 2005, the Company had total cash
and investments of approximately $48&nbsp;million and the Company had operating cash flow of
approximately $1.9&nbsp;million for the first quarter of 2005.


<P align="left" style="font-size: 10pt">&#147;As we noted in our first quarter earnings estimate on April&nbsp;1, 2005, we experienced a significant
disruption in the flow of new business in the first quarter,&#148; commented Rick Smith, Chief Executive
Officer of TASER International, Inc. &#147;However, we did see positive operating cash flow, despite
the lower sales levels.&#148; In addition, the Company had over $1&nbsp;million of export sales during the
quarter, with the majority of these sales being made into the United Kingdom, Canada and Singapore.


<P align="left" style="font-size: 10pt">&#147;During the quarter we achieved several significant milestones including the independent report
released from the Home Office of the United Kingdom on TASER X26 safety and approval for use by its
firearms officers. In addition, a review was released by the Potomac Institute for Policy Studies,
and the United States Department of Defense Human Effects Center of Excellence issued a report, all
of which provide independent answers to the question of TASER&#153; safety and support the life-saving
value of this technology.


<P align="left" style="font-size: 10pt">&#147;Numerous city councils and organizations are also reviewing policies and general orders to
assure that proper steps are taken to address the proper use of force for TASER devices in our
communities. In April, the International Association of Chiefs of Police provided a positive
nine-step review process to guide these administrators and community stakeholders in this endeavor.
In addition, the Orange County, Florida Task Force recently addressed TASER safety, use of force
guidelines and provided recommendations to the Orange County Sheriff supportive of TASER
technology.


<P align="left" style="font-size: 10pt">Our recent move to a new state of the art 100,000 square foot building was completed resulting in a
smooth transition of our headquarters, warehouse and manufacturing

<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="font-size: 10pt">operations. Our new plant will enable us to grow the business and provide production and support
expansion. We have also expanded our Research and Development team which is expected to announce
significant progress this year on many new products that we have previously disclosed, such as the
Extended Range Electronic Projectile (XREP) and the TASER Anti-Personnel Munition (TAPM), as well
as other new yet-to-be-announced products expected later this year.


<P align="left" style="font-size: 10pt">&#147;Our team of public affairs experts is very active in their continued advice and support to
the Company on public education and public relations issues with the launching of an expanded
customer and public education campaign. This includes hosting our largest user conference in
Company history including our own TASER Policy Forum in April. We just completed our distribution
of safety information to almost 100,000 police and medical opinion leaders and will continue to
conduct personal visits by senior TASER management to key existing customers and prospective new
accounts.&#148;


<P align="left" style="font-size: 10pt">&#147;We stand steadfast with our supporters and provide our best service to our customers, and will
continue to do so in the future. Most importantly, we are here to stay as the cutting-edge
innovator and market leader in the non-lethal arena for Law Enforcement, Military and Citizen
Defense,&#148; concluded Smith.


<P align="left" style="font-size: 10pt">The Company has also determined that subsequent to the issuance of its
audited financial statements
for the year ended December&nbsp;31, 2004, that there was an error in those financial statements which
resulted from the Company&#146;s calculation of the future tax benefit to be received from employees&#146;
sale of stock received from the exercise of stock options and other tax effects of stock option
exercises. Correction of this error will result in an as yet to be determined increase in deferred
tax assets, accrued expenses and additional paid-in capital and will not have a significant effect
on results of operations or cash flows. The Company is completing its analysis of the impact of
this adjustment and expects to file a Form 8-K regarding the
adjustments, which the Company will reflect by amending its Form 10-KSB for the year ended December&nbsp;31, 2004.


<P align="left" style="font-size: 10pt"><B>About TASER International, Inc.</B>


<P align="left" style="font-size: 10pt">TASER International, Inc. provides advanced non-lethal devices for use in the law enforcement,
military, private security and personal defense markets. TASER devices use proprietary technology
to safely incapacitate dangerous, combative or high-risk subjects who pose a risk to law
enforcement officers, innocent citizens or themselves. TASER technology saves lives every day, and
the use of TASER devices dramatically reduces injury rates for police officers and suspects and
reduces litigation costs. For more information on TASER life-saving technology, please call TASER
International at (800)&nbsp;978-2737 or visit our website at
<U>www.TASER.com</U>.


<P align="left" style="font-size: 10pt"><B>Note to Investors</B>


<P align="left" style="font-size: 10pt"><I>This press release contains forward-looking information within the meaning of Section&nbsp;27A of
the Securities Act of the 1933 and Section&nbsp;21E of the Securities Exchange Act of 1934, and is
subject to the safe harbor created by those sections. The forward-looking information is based upon
current information and</I>

<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="font-size: 10pt"><I>expectations regarding TASER International. These estimates and statements speak only as of the
date on which they are made, are not guarantees of future performance, and involve certain risks,
uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results
could materially differ from what is expressed, implied, or forecasted in such forward-looking
statements.</I>


<P align="left" style="font-size: 10pt"><I>TASER International assumes no obligation to update the information contained in this press
release. TASER International&#146;s future results may be impacted by risks associated with rapid
technological change, new product introductions, new technological developments and
implementations, execution issues associated with new technology, ramping manufacturing production
to meet demand, litigation including lawsuits resulting from alleged product related injuries,
media publicity concerning allegations of deaths occurring after use of the TASER device and the
negative impact this could have on sales, product quality, implementation of manufacturing
automation, potential fluctuations in quarterly operating results, adjustments to these amounts
which may be reflected in our 10Q filing, competition, financial and budgetary constraints of
prospects and customers, international order delays, dependence upon sole and limited source
suppliers, negative reports concerning TASER device uses, governmental inquiries and
investigations, medical and safety studies, fluctuations in component pricing, government
regulations, variation among law enforcement agencies with their TASER product experience, TASER
device tests and reports, dependence upon key employees, and our ability to retain employees. TASER
International&#146;s future results may also be impacted by other risk factors listed from time to time
in its SEC filings, including, but not limited to, the Company&#146;s Form 10-QSBs and its Annual Report
on Form 10-KSB.</I>


<P align="left" style="font-size: 10pt"><I>The statements made herein are independent statements of TASER International. The inclusion of any
third parties does not represent an endorsement of any TASER International products or services by
any such third parties</I>


<P align="left" style="font-size: 10pt">The Company will be hosting its first quarter earnings conference call on Tuesday, April&nbsp;19,
2005 at 9:00 a.m. EDT. The conference call is available via webcast and can be accessed on the
&#147;Investor Relations&#148; page at <U>www.TASER.com</U>. To access the teleconference, please dial: 800-237-9752
or 617-847-8706 and use the passcode: 32504988.


<P align="left" style="font-size: 10pt">For further information contact Dan Behrendt, Chief Financial Officer, (480)&nbsp;905-2000, Media Only
Hotline: (480)&nbsp;444-4000. Visit the company&#146;s web-site at
<U>www.TASER.com</U> for facts and video.



<P align="center" style="font-size: 10pt"># # #




<P align="center" style="font-size: 10pt">&nbsp;
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SUBMISSION>
